Reducing Cardiovascular Events and End-Organ Damage in Patients with Hypertension: New Considerations

References

• . Chobanian AV, Bakris GL, Black HR, ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood PRessure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252
   PubMed Web of Science ®Google Scholar
• . Mancia G, De Backer G, Dominiczak A, ; European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16(3):135–232
   PubMed Web of Science ®Google Scholar
• . Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303(20):2043–2050
   PubMed Web of Science ®Google Scholar
• . Black HR, Elliott WJ, Grandits G, ; CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289(16):2073–2082
   PubMed Web of Science ®Google Scholar
• . Cushman WC, Ford CE, Cutler JA, ; ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393–404
   PubMedGoogle Scholar
• . Andrade SE, Gurwitz JH, Field TS, . Hypertension management: the care gap between clinical guidelines and clinical practice. Am J Manag Care. 2004;10(7 pt 2):481–486
   PubMed Web of Science ®Google Scholar
• . Ogedegbe G. Barriers to optimal hypertension control. J Clin Hypertens (Greenwich). 2008;10(8):644–646
   PubMed Web of Science ®Google Scholar
• . Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008;10(2):130–139
   PubMedGoogle Scholar
• . Beevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of hypertension. BMJ. 2001;322(7291):912–916
   PubMed Web of Science ®Google Scholar
• . Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;106(3):286–288
   PubMed Web of Science ®Google Scholar
• . Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–1562
   PubMed Web of Science ®Google Scholar
• . Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345–352
   PubMed Web of Science ®Google Scholar
• . Mancini GB, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004;109(25 suppl 1):IV22–IV30
   PubMedGoogle Scholar
• . KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(2 suppl 2):S12–S154
   Web of Science ®Google Scholar
• . Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 2007;10(10 A):1151–1155
   PubMedGoogle Scholar
• . Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007;13(8 suppl B):9–20
   PubMed Web of Science ®Google Scholar
• . Brown MJ. Direct renin inhibition–a new way of targeting the renin system. J Renin Angiotensin Aldosterone Syst. 2006;7( suppl 2):s7–s11
   Google Scholar
• . Coffman TM, Crowley SD. Kidney in hypertension: Guyton redux. Hypertension. 2008;51(4):811–816
   PubMedGoogle Scholar
• . Vikrant S, Tiwari SC. Essential hypertension–pathogenesis and pathophysiology. Journal, Indian Academy of Clinical Medicine. 2001;2(3):140–161
   Google Scholar
• . Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17(11 pt 2):16S–20S; quiz A2–A4
   Google Scholar
• . Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol. 2003;42( suppl 1):S87–S91
   PubMed Web of Science ®Google Scholar
• . Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress. Lancet. 2007;370(9592):1089–1100
   PubMed Web of Science ®Google Scholar
• . Koton S, Tanne D, Bornstein NM, Green MS. Triggering risk factors for ischemic stroke: a case-crossover study. Neurology. 2004;63(11):2006–2010
   PubMedGoogle Scholar
• . Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi T, Azizi F. Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care. 2005;28(12):2823–2831
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Sowers JR; American Society of Hypertension Writing Group. ASH position paper: treatment of hypertension in patients with diabetes–an update. J Clin Hypertens (Greenwich). 2008;10(9):707–713; discussion 714–705
   PubMed Web of Science ®Google Scholar
• . Sacks FM, Svetkey LP, Vollmer WM, . Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3–10
   PubMed Web of Science ®Google Scholar
• . Rosendorff C, Black HR, Cannon CP, ; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115(21):2761–2788
   PubMed Web of Science ®Google Scholar
• . Maron DJ, Boden WE, O'Rourke RA, ; COURAGE Trial Research Group. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol. 2010;55(13):1348–1358
   PubMed Web of Science ®Google Scholar
• . ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997
   PubMed Web of Science ®Google Scholar
• . Chobanian AV. Shattuck Lecture. The hypertension paradox–more uncontrolled disease despite improved therapy. N Engl J Med. 2009;361(9):878–887
   PubMed Web of Science ®Google Scholar
• . Ellison DH, Loffing J. Thiazide effects and adverse effects: insights from molecular genetics. Hypertension. 2009;54(2):196–202
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Wild D, Parkar S, Kukin M, Messerli FH. Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol. 2008;52(13):1062–1072
   PubMedGoogle Scholar
• . Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008;117(20):2706–2715
   PubMedGoogle Scholar
• . Cutler JA, Davis BR. Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension. Circulation. 2008;117(20):2691–2704
   PubMed Web of Science ®Google Scholar
• . Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665
   PubMed Web of Science ®Google Scholar
• . Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24(7):1397–1403
   PubMedGoogle Scholar
• . Poole-Wilson PA, Swedberg K, Cleland JG, ; Carvedilol or Metroprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7–13
   PubMed Web of Science ®Google Scholar
• . Bakris GL, Fonseca V, Katholi RE, ; GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–2236
   PubMed Web of Science ®Google Scholar
• . Williams B, Lacy PS, Thom SM, . Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–1225
   PubMed Web of Science ®Google Scholar
• . Dahlof B, Sever PS, Poulter NR, . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906
   PubMed Web of Science ®Google Scholar
• . Standards of medical care in diabetes–2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Prisant LM. Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med. 2008;121( 8 suppl):S8–S15
   Google Scholar
• . Brenner BM, Cooper ME, de Zeeuw D, . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
   PubMed Web of Science ®Google Scholar
• . Lewis EJ, Hunsicker LG, Clarke WR, ; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860
   PubMed Web of Science ®Google Scholar
• . Turnbull F, Neal B, Pfeffer M, . Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25(5):951–958
   PubMedGoogle Scholar
• . Bakris GL, Williams M, Dworkin L, . Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36(3):646–661
   PubMed Web of Science ®Google Scholar
• . Jamerson K, Weber MA, Bakris GL, ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417–2428
   PubMed Web of Science ®Google Scholar
• . Patel A; ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840
   PubMed Web of Science ®Google Scholar
• . Messerli FH, Bangalore S. Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation. 2009;119(3):371–373
   PubMed Web of Science ®Google Scholar
• . Messerli FH, Makani H, Bangalore S, Benjo A, Romero Rojas J, Alviar C. Hydrochlorothiazide is inappropriate for first-line antihypertensive therapy. Presented at: 19th European Meeting on Hypertension; June 12–16, 2009; Milan, Italy
   Google Scholar
• . Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med. 2008;148(1):30–48
   PubMed Web of Science ®Google Scholar
• . Mann JF, Schmieder RE, McQueen M, ; ONTARGET Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553
   PubMed Web of Science ®Google Scholar
• . Rahuel J, Rasetti V, Maibaum J, . Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7(7):493–504
   PubMedGoogle Scholar
• . Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42(6):1137–1143
   PubMed Web of Science ®Google Scholar
• . Oh BH. Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives. Expert Opin Pharmacother. 2007;8(16):2839–2849
   PubMed Web of Science ®Google Scholar
• . Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16(3):592–599
   PubMedGoogle Scholar
• . Azizi M. Renin inhibition. Curr Opin Nephrol Hypertens. 2006;15(5):505–510
   PubMed Web of Science ®Google Scholar
• . Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39(1):E1–E8
   PubMed Web of Science ®Google Scholar
• . Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111(8):1012–1018
   PubMed Web of Science ®Google Scholar
• . Uresin Y, Taylor AA, Kilo C, . Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8(4):190–198
   PubMed Web of Science ®Google Scholar
• . Ino J, Kojima C, Osaka M, Nitta K, Yoshida M. Dynamic observation of mechanically-injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol. 2009;29(11):1858–1863
   PubMedGoogle Scholar
• . Imanishi T, Tsujioka H, Ikejima H, . Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension. 2008;52(3):563–572
   PubMed Web of Science ®Google Scholar
• . Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433–2446
   PubMed Web of Science ®Google Scholar
• . Solomon SD, Appelbaum E, Manning WJ, ; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530–537
   PubMed Web of Science ®Google Scholar
• . McMurray JJ, Pitt B, Latini R, . Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17–24
   PubMed Web of Science ®Google Scholar
• . Calhoun DA, Jones D, Textor S, . Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–1419
   PubMed Web of Science ®Google Scholar
• . Chapman N, Dobson J, Wilson S, ; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–845
   PubMed Web of Science ®Google Scholar
• . ACCORD Study GroupCushman WC, Evans GW, . Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–1585
   PubMed Web of Science ®Google Scholar
• . Dusing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin. 2006;22(8):1545–1553
   PubMed Web of Science ®Google Scholar
• . Ruilope LM, Burnier M, Muszbek N, . Public health value of fixed-dose combinations in hypertension. Blood Press Suppl. 2008;1:5–14
   PubMedGoogle Scholar
• . Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs. 2001;61(7):943–954
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719
   PubMed Web of Science ®Google Scholar
• . Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279–1283
   PubMed Web of Science ®Google Scholar
• . Weber MA, Julius S, Kjeldsen SE, . Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049–2051
   PubMed Web of Science ®Google Scholar
• . Staessen JA, Thijisq L, Fagard R, ; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22(4):847–857
   PubMed Web of Science ®Google Scholar
• . Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913
   PubMed Web of Science ®Google Scholar